| Abstract: |
Molecular virology tools are critical for basic studies of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for developing new therapeutics. Experimental systems that do not rely on viruses capable of spread are needed for potential use in lower-containment settings. In this work, we use a yeast-based reverse genetics system to develop spike-deleted SARS-CoV-2 self-replicating RNAs. These noninfectious self-replicating RNAs, or replicons, can be transcomplemented with viral glycoproteins to generate replicon delivery particles for single-cycle delivery into a range of cell types. This SARS-CoV-2 replicon system represents a convenient and versatile platform for antiviral drug screening, neutralization assays, host factor validation, and viral variant characterization. © 2021 American Association for the Advancement of Science. All rights reserved. |
| Keywords: |
controlled study; unclassified drug; human cell; genetics; nonhuman; phenotype; gene targeting; protein; drug screening; virus rna; rna synthesis; saccharomyces cerevisiae; membrane protein; molecular analysis; antivirus agent; virus genome; proteinase inhibitor; antiviral activity; replicon; drug; process optimization; virion; rna replication; virus neutralization; virus characterization; sars coronavirus; severe acute respiratory syndrome; neutralization; human; article; ic50; masitinib; cells by body anatomy; severe acute respiratory syndrome coronavirus 2; covid-19; remdesivir; sars-cov-2 antibody; coronavirus spike glycoprotein; 4 [(5,6,7,8 tetrahydro 5,5,8,8 tetramethyl 2 naphthyl)carboxamido]benzoic acid; transmembrane protein 41b; single cycle delivery
|
